Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 12/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15294419 | 0.86 | CYP3A4 (0.76) | CYP3A4CYP17A1CYP2C9CYP2C19CYP19A1 | |
| SCHEMBL6127065 | 0.79 | CYP3A4 (0.65) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL4027994 | 0.78 | CYP3A4 (0.64) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL4026634 | 0.78 | CYP3A4 (0.64) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5020196 | 0.77 | CYP3A4 (0.65) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Fumaric Acid SCHEMBL4029499 | 0.74 | CYP3A4 (0.58) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Fumaric Acid SCHEMBL7266706 | 0.74 | CYP3A4 (0.58) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL14757482 | 0.73 | CYP3A4 (1.00) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5755091 | 0.72 | CYP3A4 (0.56) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL14757461 | 0.71 | CYP3A4 (0.68) | CYP3A4CYP17A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056855-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-06-16 | — | — | US | claimed |
| EP-2632903-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2013-09-04 | — | — | EP | claimed |
| WO-2012058529-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | claimed |
| WO-2001013923-A1 | MALARIA GPI ANCHORS AS VACCINES ANTI-PARASITIC DRUGS AND FOR USE IN DIAGNOSTICS | GEORGETOWN UNIVERSITY (US) | 2001-03-01 | — | — | WO | claimed |
| EP-4168053-A1 | COMPOSITIONS AND METHODS FOR TUNABLE REGULATION OF CAS NUCLEASES | Obsidian Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11629340-B2 | DHFR tunable protein regulation | OBSIDIAN THERAPEUTICS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230092895-A1 | TANDEM CD19 CAR-BASED COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | OBSIDIAN THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230056856-A1 | COMPOSITIONS AND METHODS FOR TUNABLE REGULATION OF TRANSCRIPTION | OBSIDIAN THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4087861-A1 | COMPOSITIONS AND METHODS FOR TUNABLE REGULATION OF TRANSCRIPTION | Obsidian Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-115210250-A | Compositions and methods for regulatable regulation of transcription | 黑曜石疗法公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220213449-A1 | DHFR TUNABLE PROTEIN REGULATION | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220175781-A1 | CD40L COMPOSITIONS AND METHODS FOR TUNABLE REGULATION | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20130261135-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261135-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2633058-A2 | METHOD FOR MASS PRODUCTION OF FACTOR VII/VIIA | Hanmi Science Co., Ltd. (KR) | 2013-09-04 | — | — | EP | disclosed |
| EP-2632903-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012058529-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012057527-A2 | METHOD FOR MASS PRODUCTION OF FACTOR VII/VIIA | HANMI HOLDINGS CO., LTD. (KR) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058529-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20090069357-A1 | DEUTERIUM-ENRICHED ICLAPRIM | PROTIA, LLC (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069357-A1 | DEUTERIUM-ENRICHED ICLAPRIM | SLC10A2, DDHD2, HDHD5 | CYP3A4 1925/4885CYP17A1 2428/4885CYP2C9 1460/4885 |
| US-20130261135-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP3A4 558/4885CYP17A1 649/4885CYP2C9 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.